Biogen has developed Plegridy as a follow-on product to its leading MS therapy Avonex. Plegridy can be dosed fortnightly, compared to Avonex’s once-weekly dosing regimen. It is proposed that by attaching a polyethylene glycol link, the active interferon beta-1a component is protected from degradation, extending the lifetime of the drug and thus reducing the frequency of injections, providing a more effective and convenient dosing option.
Plegridy was first approved by the European Medicines Agency in July 2014, with the US Food and Drug Administration later approving Plegridy in August 2014, following a three-month extension to the standard review period.
LIST OF FIGURES
8 Figure 31: Rebif for multiple sclerosis – SWOT analysis
8 Figure 2: Datamonitor Healthcare’s drug assessment summary for Plegridy in multiple sclerosis
10 Figure 38: Ozanimod sales for multiple sclerosis across the US and five major EU markets, by country, 2016–25
LIST OF TABLES
4 Table 1: Plegridy drug profile
6 Table 2: Plegridy pivotal trial data in multiple sclerosis
11 Table 3: Plegridy sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.